Safety and efficacy of transjugular intrahepatic portosystemic shunt combined with palliative treatment in patients with hepatocellular carcinoma

Table 4 Outcomes of symptoms in the two groups

Symptom	Group A	Group B	P value
Control of VB within 1 mo	153 (153/168, 91.07%)	98 (98/114, 85.96%)	0.261
Absorption of RA within 1 mo	39 (39/44, 88.63%)	9 (9/22, 40.90%)	0.017
Recurrence of VB	28 (28/168, 16.67%)	56 (56/114, 49.12%)	0.023
Recurrence of RA	13 (13/44, 29.54%)	19 (19/22, 86.36%)	0.009
HE	37 (37/212, 17.45%)	12 (12/136, 8.82%)	0.036

Control of VB within 1 mo did not differ significantly between the groups (P = 0.261). Absorption of RA within 1 mo, recurrence of VB, and recurrence of RA were significantly different between the groups (P = 0.017, 0.023 and 0.009, respectively). By comparison, the rate of HE in Group B was significantly lower than in Group A (P = 0.036). VB: Variceal bleeding; RA: Refractory ascites; HE: Hepatic encephalopathy.